Abstract
Cambridge Antibody Technology plc (CAT) has established itself as a leader in the development of human monoclonal antibodies as new treatments for disease, based upon its own antibody technology. By mid-June 2004 it had one drug, HUMIRATM, a treatment for rheumatoid arthritis, approved in 41 countries including the USA and the UK, drug treatments for five conditions in Phase III and a number of other drugs at Phase I or II, or at the preclinical stage.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
